Jump to Navigation
Trends and Sentiments
Comments and Analysis
A former Goldman Sachs employee who went on to launch a...
Amazon is spending $500 million to make internet videos a...
Apple may release a brand new iMac with an incredibly...
Donald Trump can't answer a simple question that...
Loonie gains nearly half a cent on surprisingly strong...
1st of Tanzanian albino kids with missing limbs goes home
Retailers are starting the holiday season earlier than...
B&G Foods to buy General Mills’ Green Giant, Le...
4 Super-Common Interview Questions -- And 4 Super-...
A pill that prevents HIV is working even better than...
BioSante CEO Pleased With LibiGel Progress
Biotech Deal Activity Takes a Breather
Biotech Deals Keep Flowing, From Big Pharma to Industrials
Six Trades on FDA, Clinical Trial Binary Events
Biosante: Key Catalysts Should Renew Investor Interest
15 Biotech Stocks With the Lowest Put/Call Ratios
Amgen, Celgene and Novartis in the Fight Against Pancreatic Cancer
Is BioSante Pharmaceuticals Next in Line to Receive Institutional Praise?
BioSante Attracts Institutional Investors Ahead of Key FDA Catalysts in 2011
Life Sciences Companies Raise Record Amounts of Capital
Two Biotechs Poised for Gains as Call Options Boost Investor Sentiment
Two Small-Cap Biotechs and a Sector ETF to Keep You Afloat During the Market Correction
Top 24 Small Cap Stocks Being Chased by Smart Money
Biosante Pharma Up After FDA Announces Review of Testosterone Gel
Why BioSante Expects a Positive Review of Drug for Female Sexual Disorder
Platform and Specialty Pharmaceutical Companies Could Strengthen in Face of Big Pharma's Patent Cliff
7 Speculative Healthcare Stocks to Rejuvenate Your Portfolio
6 Prime Biotechs for Short and Long-Term Gains
7 Dirt-Cheap Takeover Targets in Biotech
With Cancer Vaccines in Play, Will Investors Continue to Buy-In?
3 Small Cap Biotech Companies With Future Potential
3 Micro Caps With 50% Upside Potential
Upcoming PDUFA Dates for Sub-$5 Stocks
Friday Options Brief: ADM, TRW, RDWR & BPAX
Waze Accused Of Stealing Map Data From Competing...
Troubles Loom for Emerging Market Currencies
EUR/GBP: 1.3716 USD/EUR: 1.1122 JPY/USD: 120.0550
Bullfax.com - Market News & Analysis 2008-2011
Terms & Conditions